Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Alnylam Pharmaceuticals Inc (ALNY)  
$151.22 3.82 (2.59%) as of 4:30 Thu 5/16


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 123,030,000
Market Cap: 18.60(B)
Last Volume: 934,860 Avg Vol: 724,527
52 Week Range: $143.31 - $211.65
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  824
Guru Rank Value     : 0.5
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 45,264 76,855 102,504 247,093
Total Sell Value $6,835,665 $12,957,715 $17,713,340 $48,829,179
Total People Sold 6 7 8 9
Total Sell Transactions 10 12 18 35
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 746
  Page 15 of 30  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Sharp Philip A Director   –       •      –    2017-01-18 4 OE $15.91 $238,650 D/D 15,000 155,795     -
   Maraganore John Chief Executive Officer   •       •      –    2017-01-05 4 OE $18.66 $25,004 D/D 1,340 149,710     -
   Vaishnaw Akshay EVP, R&D   •       –      –    2016-12-30 4 D $37.44 $187,200 D/D (5,000) 10,297     -
   Vaishnaw Akshay EVP, R&D   •       –      –    2016-12-30 4 OE $16.43 $187,251 D/D 9,547 15,297     -
   Maraganore John Chief Executive Officer   •       •      –    2016-12-12 4 D $42.61 $967,673 D/D (22,710) 148,370     -
   Maraganore John Chief Executive Officer   •       •      –    2016-12-12 4 OE $22.75 $685,935 D/D 30,151 171,080     -
   Greene Barry E President   •       –      –    2016-12-01 4 AS $42.61 $1,368,128 D/D (31,825) 88,584     -
   Greene Barry E President   •       –      –    2016-12-01 4 OE $22.75 $1,265,014 D/D 55,605 120,409     -
   Vaishnaw Akshay EVP, R&D, CMO   •       –      –    2016-11-30 4 AS $44.34 $1,311,998 D/D (29,165) 5,750     -
   Vaishnaw Akshay EVP, R&D, CMO   •       –      –    2016-11-30 4 OE $22.75 $663,504 D/D 29,165 34,915     -
   Pyott David E I Director   –       •      –    2016-10-13 4 B $37.00 $1,032,328 I/I 27,900 27,900 2.1     -
   Maraganore John Chief Executive Officer   •       •      –    2016-10-12 4 OE $7.10 $99,994 D/D 7,540 140,929     -
   Maraganore John CEO   •       •      –    2016-07-20 4 AS $64.29 $988,592 D/D (15,075) 133,389     -
   Maraganore John CEO   •       •      –    2016-07-20 4 OE $22.75 $342,956 D/D 15,075 148,464     -
   Maraganore John CEO   •       •      –    2016-07-19 4 AS $63.73 $961,998 D/D (15,076) 133,389     -
   Maraganore John CEO   •       •      –    2016-07-19 4 OE $22.75 $342,979 D/D 15,076 148,465     -
   Maraganore John Chief Executive Officer   •       •      –    2016-04-20 4 AS $67.38 $1,017,773 D/D (15,075) 133,389     -
   Maraganore John Chief Executive Officer   •       •      –    2016-04-20 4 OE $22.75 $342,956 D/D 15,075 148,464     -
   Maraganore John Chief Executive Officer   •       •      –    2016-04-19 4 AS $67.02 $1,016,199 D/D (15,076) 133,389     -
   Maraganore John Chief Executive Officer   •       •      –    2016-04-19 4 OE $22.75 $342,979 D/D 15,076 148,465     -
   Greene Barry E President and COO   •       –      –    2016-03-24 4 OE $7.10 $135,672 D/D 16,540 64,804     -
   Bonney Michael W Director   –       •      –    2016-03-09 4 B $58.36 $116,720 I/I 2,000 4,000 2.1     -
   Gros David-Alexandre C SVP, Chief Business Officer   •       –      –    2016-02-22 4 B $62.74 $62,749 D/D 1,000 1,000 2.74     -
   Sanofi-Aventis 10% Owner   –       –       •   2016-02-01 4 B $69.75 $14,300,843 I/I 205,030 10,256,633 1.5     -
   Maraganore John Chief Executive Officer   •       •      –    2016-01-20 4 AS $66.28 $1,047,234 D/D (15,076) 133,389     -
  746 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 15 of 30
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us